Xenetic Biosciences to acquire Santersus in all-stock exchange
Xenetic Biosciences entered a definitive all-stock share exchange to acquire Santersus, with pro forma ownership of ~15% for Xenetic holders and ~85% for Santersus holders, subject to approvals.